Articles Archives

Now Available On Demand: Preventing Advanced Therapy Program Delays with Early Supply Chain Strategy

Advanced therapy programs move through development under intense pressure. Teams are working to reach the clinic, generate data, satisfy regulatory expectations, scale operations, and ultimately deliver therapies to patients who may have limited or no other options. In that environment of competing priorities, all of which are important at the same time, supply chain decisions can become easy to defer. But as a recent roundtable webinar with XTalks made clear, decisions around cryopreservation, logistics, packaging qualification, site readiness, and documentation are not just operational details that can be solved later.

Read More

New eBook: Flexible Infrastructure for Smarter Scale in Advanced Therapies

Advanced therapy developers are being asked to do more with less. Programs need to move faster, reach more patients, support more geographies, and stay ready for evolving regulatory expectations, all while capital remains tightly managed. Cryoport Systems’ new eBook, Flexible Infrastructure: Minimizing CapEx for Smarter Scale in Advanced Therapies, explores that question across the advanced therapy lifecycle. The eBook looks at how developers can preserve capital, reduce operational risk, and avoid overbuilding fixed infrastructure before their programs are ready to use it. 

Read More

Mark Sawicki Joins Base to Base Biotech to Discuss the Future of Cell and Gene Therapy Logistics

Mark Sawicki, President and CEO of Cryoport Systems, recently joined host Jim Cornall on the Base to Base Biotech podcast for a wide-ranging conversation on the evolving cell and gene therapy landscape and the role of specialized supply chain infrastructure in supporting patient access.

Read More

How Operational Efficiency Shapes Late-Phase Manufacturability

For many advanced therapy programs, there’s a moment when the program looks like it should be able to scale cleanly, and it just... doesn’t. Not in an obvious way that can be recognized and addressed in the moment, but in the introduction of small measures of friction when the schedule doesn’t align the way it was intended to, or where time is introduced in places where it shouldn’t be.

Read More

Dominic Clarke on Reducing Variability Before it Becomes a Problem

As cell therapy programs advance, the pressure on supply chains doesn’t usually come from a single breaking point. It builds gradually, often in ways that aren’t immediately visible during early development. In a recent episode of Beyond Biotech, the podcast from Labiotech, Dominic Clarke, Vice President of IntegriCell® Technical Operations at Cryoport Systems, shares what that progression looks like.

Read More

Cryoport Systems in Labiotech on Where CGT Supply Chains Start to Break

As more cell and gene therapy programs push toward later-stage trials and commercialization, a familiar set of pressures is starting to surface. What once felt manageable at smaller scale begins to take more effort to hold together as volumes pick up. A recent article in Labiotech, developed in collaboration with Cryoport Systems, looks closely at where that strain comes from and how it often traces back to decisions made much earlier in development.

Read More

Accelerate Your Trials Without Losing Control With an End-to-End Supply Chain Model

As programs shift from Phase I to Phase II, the workload starts to overlap in new ways. Sample volumes increase as more sites operate in parallel, and activities that once occurred in sequence now run at the same time. The work itself is largely the same, but keeping it coordinated requires more time and attention.

Read More

Building Investor Confidence Through an Intentional Supply Chain Strategy

In early investment conversations, scientific innovation used to carry most of the weight. A compelling mechanism of action, a clear unmet need, and solid early data together were enough to advance the discussion and give investors a sense of potential. In today’s funding environment, however, that has shifted. Today, investors quickly move past the science and begin investigating whether a program can operate with the discipline and scalability required to grow.

Read More

2025 Year in Review: Turning Standards and Resilience into Outcomes

If you work within the advanced therapy ecosystem, you already know the story of 2025 from an industry standpoint, where science continued accelerating while funding and commercialization hinged on whether the supporting systems could keep up. For Cryoport Systems, that reality was a catalyst. This year, we raised the bar yet again and demonstrated how having the right strategic partnership behind your end-to-end supply chain can turn logistics into leverage, can transform compliance into confidence, and can spin scale into speed.

Read More